COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atorvastatin effectively lowers LDL cholesterol and cardiovascular risk.
• The additional benefit of ezetimibe (EZE), a cholesterol absorption inhibitor, to statin therapy for cardiovascular event reduction remains unclear.

Purpose of the Study:

• To evaluate if adding ezetimibe to atorvastatin further reduces cardiovascular events in patients post-acute coronary syndrome.

Main Methods:

• A 16-week, randomized, open-label trial involving 323 patients hospitalized for acute coronary syndrome.
• Patients received atorvastatin 20 mg, then were randomized to ezetimibe 10 mg/day plus atorvastatin or doubling atorvastatin dose if LDL cholesterol remained ≥1.81 mmol/L.
• Primary endpoint: composite of cardiovascular death, myocardial infarction, unstable angina, revascularization, or stroke.

Main Results:

• The atorvastatin-ezetimibe group achieved a mean LDL cholesterol of 1.60 mmol/L vs. 1.91 mmol/L in the atorvastatin-monotherapy group (p<0.001).
• Kaplan-Meier survival rate at 16 weeks was 88.1% for EZE+Statin vs. 77.0% for atorvastatin monotherapy (p=0.014).
• Ezetimibe/statin combination therapy was well tolerated.

Conclusions:

• Adding ezetimibe to atorvastatin therapy significantly lowers LDL cholesterol levels.
• Combination therapy demonstrated improved cardiovascular outcomes compared to escalating statin dose alone.
• Ezetimibe/statin combination is a safe and effective strategy for managing hyperlipidemia in high-risk patients.